Replimune Climbs on Report of Makary's Possible Ouster From FDA

Dow Jones

16小时前

By Dean Seal

Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter.

The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month.

Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year.

Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial.

Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

May 08, 2026 15:26 ET (19:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2634461988"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634461988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634461988?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 03:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634461988","market":"nz","top_or_hot":-1,"title":"Replimune Climbs on Report of Makary's Possible Ouster From FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n</p>\n<p>\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n</p>\n<p>\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n</p>\n<p>\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n</p>\n<p>\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:26 ET (19:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune Climbs on Report of Makary's Possible Ouster From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune Climbs on Report of Makary's Possible Ouster From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 03:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n</p>\n<p>\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n</p>\n<p>\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n</p>\n<p>\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n</p>\n<p>\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:26 ET (19:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634461988","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634461988","pubTimestamp":1778268360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter.The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month.Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year.Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial.Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","REPL":"Replimune Group Inc."},"translate_title":"Replimune因Makary可能被FDA驱逐的报道而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REPL":0.9,"LABU":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n\n\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n\n\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n\n\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n\n\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 15:26 ET (19:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}